Trial · NCT05090904
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1 | Brensocatib 10 mg | 62.4 | Geometric Coefficient of Variation 41.3 | nanograms per milliliter (ng/mL) | |
| Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1 | Brensocatib 25 mg | 136 | Geometric Coefficient of Variation 25.9 | nanograms per milliliter (ng/mL) | |
| Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1 | Brensocatib 40 mg | 338 | Geometric Coefficient of Variation 17.7 | nanograms per milliliter (ng/mL) | |
| Cmax of Brensocatib on Day 28 | Brensocatib 10 mg | 86.2 | Geometric Coefficient of Variation 33.1 | ng/mL | |
| Cmax of Brensocatib on Day 28 | Brensocatib 25 mg | 234 | Geometric Coefficient of Variation 37.5 | ng/mL | |
| Cmax of Brensocatib on Day 28 | Brensocatib 40 mg | 469 | Geometric Coefficient of Variation 34.0 | ng/mL | |
| Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1 | Brensocatib 10 mg | 2.0 | Full Range 1.0 to 24.8 | hours | |
| Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1 | Brensocatib 25 mg | 1.5 | Full Range 1.0 to 4.1 | hours | |
| Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1 | Brensocatib 40 mg | 1.5 | Full Range 0.6 to 24.9 | hours | |
| Tmax of Brensocatib on Day 28 | Brensocatib 10 mg | 1.9 | Full Range 0.5 to 4.0 | hours | |
| Tmax of Brensocatib on Day 28 | Brensocatib 25 mg | 2.0 | Full Range 1.0 to 4.0 | hours | |
| Tmax of Brensocatib on Day 28 | Brensocatib 40 mg | 2.0 | Full Range 1.0 to 4.0 | hours | |
| Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1 | Brensocatib 10 mg | 792 | Geometric Coefficient of Variation 49.5 | hours*ng/mL | |
| Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1 | Brensocatib 25 mg | 1600 | Geometric Coefficient of Variation 22.0 | hours*ng/mL | |
| Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1 | Brensocatib 40 mg | 3510 | Geometric Coefficient of Variation 35.0 | hours*ng/mL | |
| AUC0-24 of Brensocatib in Plasma on Day 28 | Brensocatib 10 mg | 1050 | Geometric Coefficient of Variation 33.1 | hours*ng/mL | |
| AUC0-24 of Brensocatib in Plasma on Day 28 | Brensocatib 25 mg | 3640 | Geometric Coefficient of Variation 32.7 | hours*ng/mL | |
| AUC0-24 of Brensocatib in Plasma on Day 28 | Brensocatib 40 mg | 5950 | Geometric Coefficient of Variation 40.4 | hours*ng/mL | |
| Elimination Half-life (t1/2) of Brensocatib in Plasma on Day 28 | Brensocatib 10 mg | 29.6 | Geometric Coefficient of Variation 16.5 | hours | |
| Elimination Half-life (t1/2) of Brensocatib in Plasma on Day 28 | Brensocatib 25 mg | 32.4 | Geometric Coefficient of Variation 23.0 | hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05090904/results